Total Funding
18
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Redox Pharmaceutical develops metallo-organic compounds for antiviral, antibacterial, and anti-inflammatory applications.
Ephraim Ruttner: Chief Operating Officer and Director- David Gershon: Chief Science Officer and SVP
About the Company
Redox Pharmaceutical Corporation develops a family of metallo-organic compounds for antiviral, antibacterial, and anti-inflammatory applications. The company offers Doxovir, a formulation for dermal clinical, ophthalmic herpes virus and adenovirus infections, and anti-inflammatory applications; and Doxovir-M for sexually transmitted diseases. It
offers its products for ocular applications, such as adenovirus-derived, keratoconjunctivitis, and herpetic keratitis; dermal applications, including facial herpes; non-steroidal anti-inflammatory applications; genital applications, which include HIV, human papillomavirus, and genital herpes; and medical applications. The company was founded in 1980 and is based in New York, New York.
